title: Management of Heart Failure in Cancer Patients and Cancer Survivors.
abstract: The number of cancer survivors increases annually, because of advances in detection and treatment, and the aging and growth of the population. This increase has brought a concomitant increase in morbidity and mortality from other conditions related to the adverse effects of cancer treatments. Cardiovascular diseases, and in particular left ventricular dysfunction and heart failure, are among the most significant of these. There are no unified and universally accepted evidence-based practice guidelines on the management of heartfailure in this population. This article discusses the epidemiologic impact of cancer therapeutics-related cardiac dysfunction, and reviews its most significant mediators and provides a condensed but comprehensive synopsis on its evaluation and management.
authors.affiliation: Krannert Institute of Cardiology, Indiana University, IU Health Methodist Hospital, 1801 North Senate Boulevard, MPC-2, Suite 2000, Indianapolis, IN 46202, USA. Electronic address: jefinet@iu.edu.
authors.forename: Jose Emanuel
authors.initials: JE
authors.lastname: Finet
mesh_terms: D018943:Anthracyclines / Q000009:adverse effects / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000009:adverse effects* / Q000494:pharmacology; D019468:Disease Management; D006333:Heart Failure / Q000139:chemically induced / Q000453:epidemiology / Q000628:therapy*; D006352:Heart Ventricles / Q000503:physiopathology*; D006801:Humans; D009369:Neoplasms / Q000150:complications / Q000188:drug therapy* / Q000503:physiopathology; D012307:Risk Factors; D059039:Standard of Care; D017741:Survivors / Q000706:statistics & numerical data; D016277:Ventricular Function, Left / Q000187:drug effects
chemical_list: D018943:Anthracyclines; D000970:Antineoplastic Agents
keywords: Anthracyclines; Cancer; Cardio-oncology; Cardioprotection; Cardiotoxicity; Heart failure; Myocardial dysfunction; Trastuzumab